Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04449523
Other study ID # 2020-00227
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 8, 2020
Est. completion date December 2025

Study information

Verified date June 2023
Source Insel Gruppe AG, University Hospital Bern
Contact Laurent Roten, PD Dr. med.
Phone +41 31 632 52 63
Email laurent.roten@insel.ch
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Arterial Fibrillation (AF) is well-recognized as a cause for cryptogenic Acute Ischemic Stroke (AIS) and is associated with Silent Brain Infarction (SBI). However, the role of AF in the formation of lesions (SBIs) is less well established than its role in AIS and needs clarification. The investigators hypothesize that continuous rhythm monitoring will yield a similar incidence of AF diagnosis in patients with SBI as compared to patients with cryptogenic AIS. The primary objective is to assess the cumulative incidence of AF diagnosis at 24 months in patients with SBI.


Description:

Arterial Fibrillation (AF) is well-recognized as a cause for cryptogenic Acute Ischemic Stroke (AIS) and searched for in clinical practice. However, although AF is associated with Silent Brain Infarction (SBI), its role in the formation of these lesions is less well established and needs clarification. A multitude of clinical, laboratory, echocardiographic and electrocardiographic parameters are associated with AF. Although no single one of these parameters has sufficient specificity to rule-in AF, their combined use may nevertheless help to identify patients with SBI at highest risk for AF. The study is expected to provide evidence that long term monitoring in subjects with SBI yields similar rates of AF as in AIS patients. Patients aged ≥65 years with a presumably silent brain lesion in a brain magnetic resonance imaging fulfilling inclusion criteria and consenting get a subcutaneous implantation of a cardiac monitor (Reveal LINQ). Data will be directly transferred to the treating physician by the Medtronic MyCareLink Patient Monitor. In case of a relevant arrhythmia, the respective study site will be informed by the staff of Inselspital. Relevant arrhythmias are defined as follows: - First episode of atrial fibrillation (≥30 seconds) - Sustained ventricular tachycardia (≥30 seconds) - Sustained supraventricular tachycardia (≥30 seconds) - Asystoly of ≥6 seconds duration - Atrial fibrillation with pause of ≥6 seconds duration - Higher degree atrioventricular (AV) block (3° AV bloc; 2:1 AV conduction; 2° AV block type Mobitz) - Sustained bradycardia <30 beats per minute (≥30 seconds) It is the responsibility of the respective study sites to take appropriate actions and inform the patients and treating physicians about relevant findings. The maximal timeframe from data transmission to data analysis is one week and from data transmission to patient notification two weeks. The expected results of the study would be supportive in introducing long term monitoring to the care pathway in subjects with SBI. Since SBI are more prevalent than AIS and current recommendations very restrictive, this would have a relevant impact on SBI management.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Age - = 65 years - = 50 years AND one the following: - NT-proBNP >400 pg/mL - Left atrial ventricular index >42 ml/m2 or left atrial diameter >46 mm - Covert infarctions with cortical involvement in more than one vascular territory (left carotid territory, right carotid territory, vertebrobasilar territory) - Written informed Consent - Any clinically silent ischemic lesions of the brain parenchyma detected on neuroimaging defined according to established criteria as either: - Diffusion weighted imaging (DWI) positive lesions: Focus of restricted diffusion (high DWI signal and low apparent diffusion coefficient value) occurring in either white or gray matter, located in the cerebrum, cerebellum, or brain stem AND not satisfying the diagnostic criteria for multiple sclerosis OR - Cavitatory Lesions: = 3 mm in size that follow cerebro-spinal fluid on all sequences that are slit or wedge shaped with an irregular margin AND NOT longitudinally aligned with perforating vessels or with a multiple, bilateral symmetrical distribution OR - T2 weighted (T2W) hyperintense/T1 weighted (T1W) hypointense lesions: - Focal lesion with high T2W signal and low T1W signal that have prior evidence of restricted diffusion; OR - Present within cortical gray matter or deep gray matter nuclei OR - A lesion that is new, compared with an MRI performed within 3 months OR - T2W hyper/T1W hypointense lesions in the white matter, which are discontinuous but associated with the classic confluent periventricular T2 intense change of leukoaraiosis (Fazekas =2) AND NOT satisfying the diagnostic criteria for multiple sclerosis or with a significant patient history of severe trauma, radiation, drug toxicity, or carbon monoxide poisoning Exclusion Criteria: - History of AF or atrial flutter - Patients with a history of symptoms compatible with an AIS, covert neurological deficits are allowed. - Cardiac implantable electronic devices (pacemaker, implantable cardiac defibrillator (ICD), implantable cardiac monitor (ICM)) - Indication for cardiac implantable electronic device implantation (pacemaker, ICD, ICM) - History of or indication for major cardiac surgery or transcutaneous aortic valve implantation - Indication for permanent oral anticoagulation - Contraindication for permanent oral anticoagulation - Projected life expectancy of less than 2 years - Active intra- or extracranial high-grade malignancy - Patient is already included in another clinical trial that will affect the objectives of this study - Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the study and to formulate his/her own wishes correspondingly - Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. - Known or suspected non-compliance, drug or alcohol abuse

Study Design


Locations

Country Name City State
Austria Universitätsspital Graz Graz
Germany Charite Berlin Berlin
Switzerland Kantonsspital Aarau Aarau
Switzerland University Hospital Basel Basel
Switzerland Inselspital Bern Bern
Switzerland Centre hospitalier universitaire vaudois (CHUV) Lausanne Vaud
Switzerland Kantonsspital St.Gallen Saint Gallen
Switzerland Universitätsspital Zurich Zurich

Sponsors (1)

Lead Sponsor Collaborator
Insel Gruppe AG, University Hospital Bern

Countries where clinical trial is conducted

Austria,  Germany,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Time to first diagnosis of AF (lasting =30 seconds; =6 minutes; =1 hour; = 24 hours) until battery depletion of Implantable Cardiac Monitor (ICM) (36-42 month). From day 0 until battery depletion, expected to be 36 to 42 months
Other Cumulative incidence of AF diagnosis until battery depletion of ICM From day 0 to until battery depletion, expected to be 36 to 42 months
Primary Cumulative incidence of Arterial Fibrillation (AF) diagnosis over a median of 24 months Only adjudicated events will be used for the analysis. An AF episode is defined as lasting more than 30 seconds. A diagnosis of atrial flutter will also be considered as a primary endpoint. From day 0 to 24 months after inclusion
Secondary Time to first diagnosis of AF (lasting =30 seconds; =6 minutes; =1 hour; = 24 hour) From day 0 to 24 months after inclusion
Secondary Burden of AF The burden of AF is defined as the amount of time (percentage) in AF during rhythm monitoring. AF burden will be calculated on a monthly basis. From day 0 to 24 months after inclusion
Secondary Time to composite of first diagnosis of AF, stroke and death. From day 0 to 24 months after inclusion
Secondary Incidence of AF diagnosis according to Silent Brain Infarction (SBI) neuroradiological appearance (subcortical small vessel versus embolic pattern involving grey matter) and SBI fulfilling ESUS criteria versus lacunar type. Embolic stroke of undetermined source (ESUS) From day 0 to 24 months after inclusion
Secondary Start of oral anticoagulation therapy at 24 months. At 24 months
Secondary Stroke at 24 months At 24 months
Secondary Mortality at 24 months At 24 months
Secondary Prevalence of other possible etiologies for SBI according to a modified TOAST-classification (large artery disease, small artery disease, other specific etiologies, unknown etiology, incomplete workup) From day 0 to 24 months after inclusion
Secondary Incidence of new SBI at 24 months (only if sufficient funding can be obtained for repeat brain MRI at 24 months without contrast agent) At 24 months
See also
  Status Clinical Trial Phase
Completed NCT00831259 - Risk of Stroke in Pulmonary Embolism With a Patent Foramen Ovale (PFO) N/A
Recruiting NCT05369195 - Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion N/A
Active, not recruiting NCT04808778 - Stroke Prevention in Young Adults With Sickle Cell Anemia
Completed NCT04241289 - Detection and Neurological Impact of Cerebrovascular Events in Cardiac Surgery Patients
Recruiting NCT05685069 - Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions
Not yet recruiting NCT04457908 - The Effectiveness and Cost Effectiveness of Intelligent Assessment of Gait Disorder in Silent Cerebrovascular Disease N/A
Not yet recruiting NCT04456348 - Association Between Gait Assessed by Intelligent System and Cognitive Function in Silent Cerebrovascular Disease
Completed NCT04734587 - Evaluation of Brain Damage Due to Coronary Angioplasty in Percutaneous Intervention Patients
Completed NCT03104556 - Silent sTROke duriNG MitraClip Implantation